Medicine in Our Life

 https://libgen.gs/

  References Allaqaband S, Kirvaitis R, Jan F, et al. Endovascular treatment of peripheral vascular disease.  Curr Probl Cardiol.  2009;34:359-476. Almasri J, Adusumalli J, Asi N, et al. A systematic review and meta-analysis of revascularization outcomes of infrainguinal chronic limb-threatening ischemia.  Eur J Vasc Endovasc Surg.  2019;58(1S):S110-S119. Bonaca MP, Nault P, Giugliano RP, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: Insights from the FOURIER Trial (further cardiovascular outcomes research with pcsk9 inhibition in subjects with elevated risk).  Circulation.  2018;137(4):338-350. Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization.  N Engl J Med.  2020;382(21):1994-2004. Conte MS, Bradbury AW, Kolh P, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia.  Eur J Vasc Endovasc Surg.  2019;58(1S):S1-S109.

  sumber: https://www.microsoft.com/en-us/research/project/academic/articles/microsoft-academic-to-expand-horizons-with-community-driven-approach/ Next Steps for Microsoft Academic – Expanding into New Horizons May 4, 2021 Share on Twitter   Share on Facebook   Share on LinkedIn   Share on Reddit   Subscribe to our RSS feed Editor’s note, June 4, 2021 –  the post has been updated with a more extensive FAQ to provide more details on the changes announced May 4. For over seven years, Microsoft Research has been proud to have one of its AI research projects contribute to the open exchange of knowledge within the research community. We are now evolving our focus to explore how we can advance these AI technologies in Microsoft 365 to empower every person and organization to derive valuable insights from their content. We remain confident in open and community-driven alternatives to MAS and are pleased to see the recent momentum across the academic ecosystem. Many of our open-source  machine